Abstract
The diagnosis of OTC deficiency is made by assay of OTC activity in the liver of an affected proband, or by measurement of orotic acid +/orotidine excretion in the urine after a protein or amino acid load or after a single dose of allopurinol in a proband or suspected carrier (see Chapter 8 for details). If prenatal diagnosis is desired, these approaches are less useful. OTC activity is not expressed in amniocytes and there are no unusual metabolites found in the amniotic fluid in OTC deficiency. Fetal liver biopsies are possible in order to assay urea cycle enzymes but are quite risky to the pregnancy(219–221). Thus molecular genetic approaches have been developed to solve this problem.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Snodgrass, P.J. (2004). Molecular Pathology of OTC Deficiency. In: Ornithine Transcarbamylase. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9062-4_5
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9062-4_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4020-7683-1
Online ISBN: 978-1-4419-9062-4
eBook Packages: Springer Book Archive